Epigral Ltd

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 May 2026, providing investors with an up-to-date view of its performance and outlook.

Epigral Ltd has witnessed a notable improvement in its valuation parameters, shifting from very attractive to attractive territory, despite ongoing challenges in the specialty chemicals sector. This recalibration reflects a more balanced price-to-earnings (P/E) and price-to-book value (P/BV) ratio relative to its historical averages and peer group, signalling a potential inflection point for investors assessing the stock’s price attractiveness.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Epigral Ltd, a small-cap player in the specialty chemicals sector, has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating. This change comes amid a backdrop of mixed market returns and a sector characterised by expensive peer valuations, positioning Epigral as a potentially compelling investment opportunity despite recent share price volatility.

Epigral Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting a recalibration of price attractiveness within the specialty chemicals sector. This change comes amid a strong price rally and improved relative valuation metrics compared to its peers, signalling potential opportunities for investors despite a cautious overall market stance.

Epigral Ltd, a specialty chemicals company, has reported a mixed set of financial results for the quarter ended March 2026, reflecting a shift from a previously flat to a negative financial trend. While net sales and profit before tax have shown encouraging growth, key profitability metrics and operational ratios have deteriorated, signalling challenges ahead for this small-cap stock.

The Sensex advanced 0.76% on 4 May 2026, yet Epigral Ltd outpaced the broader market with a remarkable 15.35% gain, reaching an intraday high of Rs 1378. This 12.61-percentage-point outperformance over its Specialty Chemicals sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Epigral Ltd., the specialty chemicals manufacturer formerly known as Meghmani Finechem Ltd., reported a consolidated net profit of ₹80.95 crores for Q4 FY26, marking a dramatic 106.98% quarter-on-quarter surge but a 6.84% year-on-year decline. The ₹5,211-crore market capitalisation company witnessed its shares trade at ₹1,203.25 on April 30, 2026, representing a modest 0.56% gain following the results announcement, though the stock remains 43.09% below its 52-week high of ₹2,114.30.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, a rating that was last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

The Sensex climbed 1.23% on 10 Apr 2026, yet Epigral Ltd outpaced the broader market with a 7.36% gain, touching an intraday high of Rs 1084.75. This 5.06 percentage-point outperformance over its Specialty Chemicals sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

The Sensex advanced 4.03% on 8 Apr 2026, yet Epigral Ltd outpaced both the benchmark and its sector with a 7.28% gain, touching an intraday high of Rs 1022.6. This 4.65-percentage-point outperformance signals a distinctly stock-specific rally rather than a broad market lift.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has exhibited a notable shift in price momentum and technical indicators, reflecting a complex market stance. Despite a strong intraday gain of 6.01% to close at ₹954.40 on 8 Apr 2026, the stock’s technical parameters reveal a nuanced picture with mixed signals across weekly and monthly timeframes.